Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Molecular genetics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Molecular genetics. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-002387-32 Sponsor Protocol Number: UoL001019 Start Date*: 2014-08-05
    Sponsor Name:University of Liverpool
    Full Title: Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis
    Medical condition: Aminoglycoside-induced nephrotoxicity
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    18.0 10022891 - Investigations 10069022 Kidney injury molecule-1 PT
    18.0 100000004857 10067571 Nephrotoxicity LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005475-41 Sponsor Protocol Number: MLX Start Date*: 2014-11-05
    Sponsor Name:UZ Brussel
    Full Title: Sulfamethoxazole treatment of primary PREPL deficiency
    Medical condition: Hypotonia-cystinuria syndrome and isolated PREPL deficiency.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001482-57 Sponsor Protocol Number: SAKK_41/13-Aspirin Start Date*: 2016-09-19
    Sponsor Name:SAKK Swiss Group for Clinical Cancer Research
    Full Title: Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial
    Medical condition: PIK3CA mutated colon cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000649-39 Sponsor Protocol Number: EMR62202-502 Start Date*: 2004-12-01
    Sponsor Name:Merck KGaA
    Full Title: A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalat...
    Medical condition: Metastatic colorectal cancer refractory to irinotecan treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000684-16 Sponsor Protocol Number: 03MI10 Start Date*: 2010-01-21
    Sponsor Name:Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
    Full Title: Gene therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector.
    Medical condition: X-Linked severe combined Immunodeficiency (SCID-X1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010099 Combined immunodeficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003573-26 Sponsor Protocol Number: TRAMAV02092019 Start Date*: Information not available in EudraCT
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated
    Medical condition: Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005066-30 Sponsor Protocol Number: RG_14-088 Start Date*: 2018-03-20
    Sponsor Name:The University of Birmingham
    Full Title: MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with ...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplastic syndrome(MDS) and isolated myeloid sarcoma (either de novo or secondary) are eligible for the trial.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003836-77 Sponsor Protocol Number: OCTO-003 Start Date*: 2008-12-09
    Sponsor Name:University of Oxford
    Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis.
    Medical condition: Barrett's Metaplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001935-12 Sponsor Protocol Number: AIEOP-BFM-ALL-2017 Start Date*: 2018-07-02
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
    Medical condition: acute lymphoblastic leukemia in children and adolescents <18 years of age
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000405-22 Sponsor Protocol Number: TE23 Start Date*: 2005-02-25
    Sponsor Name:Medical Research Council
    Full Title: TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.
    Medical condition: Poor prognosis male germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043333 Testicular germ cell tumour mixed stage III LLT
    9.1 10015802 Extragonadal primary germ cell tumour mixed stage III LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003971-37 Sponsor Protocol Number: PRIMUS004 Start Date*: 2020-08-19
    Sponsor Name:NHS Greater Glasgow and Clyde Health Board [...]
    1. NHS Greater Glasgow and Clyde Health Board
    2. University of Glasgow
    Full Title: PRIMUS 004: A multi-arm non-comparative signal seeking phase II platform trial of biomarker-directed novel second-line treatments in metastatic pancreatic cancer
    Medical condition: Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001262-28 Sponsor Protocol Number: MSC-TENDO-2015 Start Date*: 2017-08-21
    Sponsor Name:Institut de Terapia Regenerativa Tissular S.L. (ITRT)
    Full Title: Treatment of Refractory Patellar Tendinopathy with MSV *. Comparative study with P-PRP *MSV are bone marrow autologous mesenchymal stem cells, selected and cultured under Good manufacturing Practic...
    Medical condition: Patients diagnosed with patellar tendinopathy with a minimum of 4 months evolution and have presented two acute episodes, refractory to standard treatments present a gap equal or greater than 3 mm ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10034123 Patellar tendinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001394-87 Sponsor Protocol Number: EBSTEM001 Start Date*: 2012-11-16
    Sponsor Name:King's College London
    Full Title: A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa.
    Medical condition: Recessive Dystrophic Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000251-89 Sponsor Protocol Number: 1042-0800 Start Date*: 2014-10-22
    Sponsor Name:Antwerp University Hospital
    Full Title: A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome
    Medical condition: behavioral problems in children with fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001612-20 Sponsor Protocol Number: ML21445 Start Date*: 2008-05-29
    Sponsor Name:ROCHE
    Full Title: A study of chlorambucil plus MabThera as induction therapy followed in responders by maintenance therapy versus observation on response rate in patients ≥ 60 years with previously untreated ...
    Medical condition: CD20+ CLL, Binet stage C or Binet stages A-B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005017-41 Sponsor Protocol Number: AIEOP-BFM_2017_POLAND Start Date*: 2021-04-23
    Sponsor Name:Medical University of Silesia
    Full Title: AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study...
    Medical condition: Acute Lymphoblastic Leukemia in children and adolescents <18 years of age
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018980-41 Sponsor Protocol Number: Pediatric_Relapsed_AML2010/01 Start Date*: 2013-10-15
    Sponsor Name:German Society of Pediatric Hematology and Oncology gGmbH (GPOH gGmbH)
    Full Title: International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia
    Medical condition: Pediatric relapsed or refractory AML
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) DK (Prematurely Ended) CZ (Prematurely Ended) NL (Ongoing) SE (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005874-11 Sponsor Protocol Number: 0822-035 Start Date*: 2009-02-24
    Sponsor Name:Laboratoires Merck Sharp & Dhome-Chibret
    Full Title: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of ...
    Medical condition: This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031283 Osteoporosis fracture LLT
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001671-30 Sponsor Protocol Number: 2013-TL-MEL-Th Start Date*: 2015-07-31
    Sponsor Name:Centre Eugène Marquis
    Full Title: Evaluation of cobimetinib + vemurafenib combination treatment in patients with brain metastasis BRAFV600 mutated cutaneous melanoma
    Medical condition: Patients with brain metastasis (BM) from BRAFV600-mutated cutaneous melanoma. Patients will be enrolled into three cohorts: A. Neurologically asymptomatic patients who have not received prior loc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003857-73 Sponsor Protocol Number: D6130C00003 Start Date*: 2019-09-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refr...
    Medical condition: Treatment Naïve or Relapsed/Refractory Acute Myeloid Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 01:04:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA